Literature DB >> 28185685

[New TNM classification of non-small cell lung cancer].

G Chassagnon1, S Bennani2, M-P Revel2.   

Abstract

Initial staging is a key part of the initial evaluation of non-small cell lung cancer. It relies on the 7th edition of the TNM classification. Proposals have been recently developed for the 8th edition of the classification, which is due to be enacted in early 2017. Among these proposals, the weight of tumor size has been increased and new N descriptors have been introduced to further describe N category depending on the number station involved. Regarding M descriptors, oligometastatic disease is distinguished from multiple distant extrathoracic metastases.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cancer du poumon non à petites cellules; Computed tomography; Ganglion; Lymph node; Metastasis; Métastase; Non-small cell lung cancer; Scanner; Stadification; Staging; TNM

Mesh:

Year:  2017        PMID: 28185685     DOI: 10.1016/j.pneumo.2016.12.006

Source DB:  PubMed          Journal:  Rev Pneumol Clin        ISSN: 0761-8417


  8 in total

1.  Clinical evaluation of contrast-enhanced CT combined with PET/CT in diagnosis of mediastinal lymph node metastasis of non-small-cell lung cancer.

Authors:  Xiaodong Li; Xiaomeng Zheng; Tianle Zhang; Xi Dong; Jian Su
Journal:  Pak J Med Sci       Date:  2022 May-Jun       Impact factor: 2.340

2.  Overexpression of 14-3-3ζ in lung tissue predicts an improved outcome in patients with lung adenocarcinoma.

Authors:  Man Li; Hailing Lu; Xiaolian Liu; Qingwei Meng; Yanbin Zhao; Xuesong Chen; Jing Hu; Wei Liu; Li Cai
Journal:  Oncol Lett       Date:  2018-05-18       Impact factor: 2.967

3.  MicroRNA‑208a directly targets Src kinase signaling inhibitor 1 to facilitate cell proliferation and invasion in non‑small cell lung cancer.

Authors:  Li Liu; Wuzhang Wang; Song Gao; Xiuwen Wang
Journal:  Mol Med Rep       Date:  2019-07-31       Impact factor: 2.952

4.  Downregulation of long non-coding RNA LINC-PINT serves as a diagnostic and prognostic biomarker in patients with non-small cell lung cancer.

Authors:  Chunjie Zhang; Cuixue Gong; Jianzhao Li; Jiaying Tang
Journal:  Oncol Lett       Date:  2021-01-18       Impact factor: 2.967

5.  Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.

Authors:  Tao Hong; Teng Sun; Miao Zhang; Xinlong Liu; Yanliang Yuan; Ponnie Robertlee Dolo; Bi Chen; Hao Zhang
Journal:  Thorac Cancer       Date:  2021-08-30       Impact factor: 3.500

6.  Tanshinone IIA inhibits cell growth by suppressing SIX1-induced aerobic glycolysis in non-small cell lung cancer cells.

Authors:  Hailiang Qi; Zhengyi Chen; Yuhuan Qin; Xianlei Wang; Zhihua Zhang; Yazhai Li
Journal:  Oncol Lett       Date:  2022-04-21       Impact factor: 2.967

7.  A Clinical Study on the Use of Yiqi Yangxue Decoction Combined with Chemotherapy to Promote Rapid Postoperative Recovery in Patients with Non-Small Cell Lung Cancer.

Authors:  Junyan Liang; Yue Wang; Ling Zheng; Hui Mei
Journal:  Emerg Med Int       Date:  2022-09-09       Impact factor: 1.621

8.  To explore the prognostic value of spread through air spaces and develop a nomogram combined with spread through air spaces in lung squamous cell carcinoma.

Authors:  Hongyan Yu; Chengbin Lin; Xiaohan Chen; Zheng Wang; Weiyu Shen
Journal:  J Thorac Dis       Date:  2022-09       Impact factor: 3.005

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.